Radiopharm Theranostics Ltd (ASX: RAD) Share Price and News

Mr Hains has over 30 years of experience in roles with a portfolio of ASX and NASDAQ listed companies.

Mr. Hopper brings 20 years' experience in the management and funding of biotechnology and healthcare companies in Australia and the United States. Former directorships in last 3 years: Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.

Mr Turner, since August 2022, is also non-executive director at AtomVie Global Radiopharma Inc, a global contract development and manufacturing organization, launched by the Centre for ProbeDevelopment and Commercialisation (CPDC). Mr. Turner was a director of Coqui Pharmaceuticals from November 2014 to March 2019. Mr.Turner was Chief Executive Officer at Siemens Radiopharmaceuticals, which operated a global PET radio-pharmacy network, from 2010 to 2012. Prior to that, he was General Manager of ANSTO Radiopharmaceuticals, which was Australia's manufacturer of radioisotopes for the nuclear medicine sector. Since 2013, Mr. Turner is the CEO of the Turner Group LLC, a boutique management consulting firm that advises institutional investors on acquisition targets in the field of nuclear medicine, radiochemicals and radiopharmaceuticals He chairs risk committee.

Mr.Canevari was previously Chief Commercial Officer of Novartis company, Advanced Accelerator Applications, from April 2020 to September2021, one of the radiopharmaceutical and nuclear medicine companies globally. He was responsible for commercial strategy and country organizations in approximately 20 countries across North America, Europe and Asia. Prior to that, he was Senior Vice President and Global Head of the Breast Cancer Franchise for Novartis Oncology from 2017, where he oversaw the launch of breast cancer products. Mr. Canevari has also held management roles with Novartis Pharma and Ethicon/Johnson & Johnson.

Ms. Larkin is currently the Managing Director of Hester Larkin Associates Consulting. Since 2008 in this role, she has been providing consulting services to diagnostic imaging, pharmaceutical and biotech companies in projects ranging from pre-clinical, clinical, submission to the European Medicines Agency, EU medical advisory boards, EU manufacturing and commercial partnerships. Ms. Larkin has also held several board director and trustee positions in the United Kingdom and Belgium and currently sits on the board of directors of two charities. Prior to this, Ms. Larkin was the EMA General Manager BMS Medical Imaging at Bristol-Myers Squibb from 2002 to 2008 and held roles in European marketing, European business development and general management at DuPont Pharmaceuticals from 1983 to 2008. She is member of risk committee.

Dr. Alland is a biotech advisor working with entrepreneurs and investors to advance diagnostic and therapeutic products for oncology and rare diseases. Dr. Alland also serves on the board of directors of Abeona Therapeutics (NASDAQ: ABEO), a cell and gene therapy company. Previously, Dr. Alland served as CMO of PMV Pharma (NASDAQ, PMVP),an oncology company, and prior to that, as CMO of Affimed (NASDAQ: AFMD), an immuno-oncology company, and as CMO of Tarveda Therapeutics, a targeted drug conjugate company. Her career includes leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of Tagrisso, Opdivo, Tasigna, and Caelyx. As Head of Oncology Early Clinical Development at AstraZeneca, she oversaw the company's early oncology portfolio. She completed training in Pediatrics at the Children's Hospital of Philadelphia, and Hematology/Oncology at MemorialSloan-Kettering, and served on the faculty of Albert Einstein College of Medicine. She is Member of risk committee.

Mr Donnelly brings over 25 years of leadership experience in finance, strategy, and operations within the biopharmaceutical and biotechnology industries. He has a track record of building and leading cross-functional teams, driving corporate governance, and executing complex financial strategies that support rapid company growth. Currently serving as Chief Financial Officer at PepGen Inc. Before joining PepGen, Mr Donnelly was CFO at EIP Pharma (now CervoMed. His career also includes a 15-year tenure at Takeda/Shire PLC, where he held various senior roles, including Vice President of R&D Business Operations. In addition to his operational expertise, Mr Donnelly is experienced in business partnering, valuation, investor relations, and decision support analysis, making him a trusted advisor to both executive leadership teams and boards of directors.

-

-

-

-

-